CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Pharmacological activity and analytical methods for determination of fampridine – a drug for multiple sclerosis treatment

Author: 
Dobrina D Tsvetkova, Danka P Obreshkova and Petar Y Atanasov
Subject Area: 
Health Sciences
Abstract: 

Background: Multiple sclerosis is a chronic autoimmune disease of the central nervous system, characterized by inflammation, demyelinization and axonal injury. The current therapeutic strategies include: disease-modifying, immunomodulatory and immunosuppressive agents (Mitoxantrone). Immunomodulatory drugs are Interferon β, Glatiramer acetate, Leflunomide, Teriflunomide, Fingolimod, Laquinimod (with dual properties of immunomodulation and neuroprotection). For the treatment of relapsing-remitting and secondary progressive multiple sclerosis, new trend is the application of a specific therapeutic strategy with monoclonal antibodies: Alemtuzumab, Daclizumab, Natalizumab and Rituximab. Objective: The purpose of the study is the summarizing of the data for pharmacological activity and analytical methods for determination of a drug for treatment of multiple sclerosis – Fampridine. Methods: The method of literature survey of data for pharmacological action of Fampridine and analytical methods has been applied. Results: For pharmacological activity, literature survey has been shown, that 4-aminopyridine (Ampyra, Dalfampridine, Fampridine, Pymadine), as a selective voltage-dependent potassium channel blocker in the neuronal membrane, prolongs the depolarization phase of the action potential, improves axon potential propagation, increase neurotransmitter release at the neuromuscular junction. Fampridine has been used clinically for multiple sclerosis and Lambert-Eaton myasthenic syndrome. The combination Nivalin P: Galantamine hydrobromide/Pymadine is promising for Alzheimer's disease, due to the synergistic effect of cholinergic potentiation components: Galantamine hydrobromide as an acetylcholinesterase inhibitor and Pymadine as a stimulant of presynaptic release and synthesis of acetylcholine. For the analysis of related substances in 4-aminopyridine substance have been developed gradient HPLC method with UV-detection and capillary electrophoresis. For determination of 4-aminopyridine in capsules, serum and urine have been presented HPLC methods with UV-detection. For analysis of 4-aminopyridine in plasma capillary electrophoresis, spectrofluorimetry, gas chromatography with electron capture detector and HPLC with UV-detection have been described. Conclusion: The main pharmacological application of Fampridine is for treatment of multiple sclerosis and the combination Nivalin P: Galantamine hydrobromide/Pymadine is promising for Alzheimer's disease. As the most often applied methods for analysis of 4-aminopyridine in dosage forms and biological samples have been presented HPLC methods with UV-detection, gas chromatography and capillary electrophoresis.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran